True North Labs

Author: labstruenorth@gmail.com

  • New Phase 2 Trial Explores Adding Pelareorep to Standard Therapy for Advanced Colorectal Cancer

    New Phase 2 Trial Explores Adding Pelareorep to Standard Therapy for Advanced Colorectal Cancer

    A new multicenter Phase 2 clinical trial has launched to evaluate a potential new approach for patients battling metastatic colorectal cancer that has progressed after initial treatment. The study, registered on ClinicalTrials.gov, will compare the standard combination of FOLFIRI chemotherapy and bevacizumab against that same regimen with the addition of pelareorep, an investigational therapeutic agent being explored for its potential to enhance anti-tumor activity.

    The trial specifically targets patients with RAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer who have already progressed after one prior line of oxaliplatin-based therapy. This is a particularly challenging patient population, as RAS-mutated and MSS tumors have historically been less responsive to certain newer immune-based treatments, making the search for effective second-line options especially important for both patients and clinicians.

    By using a randomized, open-label design, researchers aim to generate clear comparative data on both efficacy and safety between the two treatment arms. This structured approach reflects the kind of rigorous science needed to determine whether adding pelareorep to a well-established chemotherapy backbone can meaningfully improve results for patients facing limited options after their cancer has progressed.

    The initiation of this trial is an encouraging sign of continued innovation in the oncology field, particularly for hard-to-treat cancer subtypes. Second-line treatment trials like this one are essential steps in the broader effort to expand the toolkit available to oncologists, and successful outcomes could eventually open the door to new combination therapy options for a patient population that currently has relatively few targeted alternatives.

    While it will take time before results are available, the launch of this Phase 2 study represents meaningful progress in cancer research and reflects the ongoing commitment of the research community to improving outcomes for people living with metastatic colorectal cancer. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

  • University of Cincinnati Begins Clinical Trial Targeting Prosthetic Joint Infections

    The University of Cincinnati has taken an important step forward in the fight against prosthetic joint infections, announcing that the first patients have been enrolled in a new clinical trial designed to explore improved treatment options for this challenging condition. Prosthetic joint infections can be difficult to treat and often require lengthy antibiotic regimens or additional surgeries, so any research that could lead to better outcomes is a welcome development for patients and the broader orthopedic community.

    While specific details about the trial’s methodology and treatment approach continue to emerge, the enrollment of initial participants marks a meaningful milestone. Clinical trials like this one are essential building blocks in the search for more effective therapies, and reaching the patient enrollment stage reflects months or years of preparatory research, regulatory review, and institutional collaboration coming to fruition.

    Academic medical centers like the University of Cincinnati play a critical role in advancing treatments for complex conditions that affect quality of life for many patients, particularly older adults and those who have undergone joint replacement surgery. Prosthetic joint infections remain one of the more difficult complications in orthopedic medicine, and progress in this area could eventually mean fewer revision surgeries, shorter recovery times, and better long-term outcomes for patients who rely on joint replacements to stay active and mobile.

    The broader peptide and biomedical research community will likely watch this trial with interest, as innovative approaches to infection management continue to gain attention across multiple areas of medicine. As the trial progresses and more patients are enrolled, researchers will gather valuable data that could inform future treatment protocols and potentially benefit patients well beyond the initial study population.

    True North Labs will continue to follow developments in this space as they unfold. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: UC enrolls first patients in clinical trial for prosthetic joint infections – University of Cincinnati

  • FDA Advisory Panel Gives Nod to Six Promising Peptides

    In an encouraging development for the peptide community, an FDA advisory panel has given its backing to six specific peptides, signaling growing recognition of their potential therapeutic value. While advisory panel support is not the same as full regulatory approval, it represents an important step in the broader conversation about how these compounds might be safely studied and eventually made available to more people.

    Peptides have generated substantial interest in recent years for their roles in areas ranging from metabolic health to tissue repair and recovery. When an FDA advisory body takes the time to evaluate and voice support for particular compounds, it often reflects a careful review of existing research, safety data, and potential benefits. This kind of engagement can help create a clearer pathway for further clinical investigation.

    For researchers and clinicians who have been following the peptide space, this kind of regulatory attention is a welcome sign. It suggests that the scientific community and regulatory bodies are taking a closer look at how these molecules work and where they might fit into modern medicine. Advisory panel input can also help set the stage for more standardized manufacturing practices and quality controls, which benefits everyone from researchers to patients.

    It’s worth noting that advisory panel recommendations are just one part of a longer regulatory journey. Additional studies, safety monitoring, and formal FDA decisions typically follow before any compound becomes widely available through approved channels. Still, this kind of forward movement is meaningful, as it reflects a thoughtful, evidence-based approach to evaluating peptide therapies rather than dismissing them outright.

    As this story develops, it will be worth watching how these six peptides progress through the regulatory process and what additional research emerges to support their potential uses. For now, this represents a hopeful step forward for the peptide field and those who follow its progress closely.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: What to Know About the 6 Peptides Backed by an FDA Advisory Panel – Verywell Health

  • TearSolutions’ Peptide Therapy Lacripep Moves Into Phase 2 Trial for Neurotrophic Keratitis

    TearSolutions’ Peptide Therapy Lacripep Moves Into Phase 2 Trial for Neurotrophic Keratitis

    TearSolutions has announced that its investigational peptide therapy, Lacripep, is moving into a Phase 2 clinical trial for the treatment of neurotrophic keratitis, a rare and potentially vision-threatening condition caused by reduced corneal sensation. The advancement follows the U.S. Food and Drug Administration granting the therapy two separate special designations, underscoring regulatory recognition of its potential to address a significant unmet medical need.

    Lacripep is derived from lacritin, a naturally occurring protein found in human tears that plays a role in maintaining a healthy ocular surface. By harnessing a peptide fragment of this natural protein, TearSolutions aims to restore protective tear film function and support corneal healing in patients whose eyes have lost normal sensory feedback due to nerve damage. Neurotrophic keratitis can lead to persistent epithelial defects and, if untreated, more serious complications, making new therapeutic options especially valuable for patients and eye care specialists alike.

    The dual FDA designations granted to Lacripep are typically awarded to therapies that show promise for treating rare or serious conditions with limited existing treatment options. These designations can provide benefits such as closer collaboration with regulators, potential eligibility for expedited review pathways, and additional development incentives — all of which can help accelerate the path toward patients who need new options.

    Moving into Phase 2 testing represents an important step in validating earlier research suggesting that Lacripep may help promote corneal surface repair using a naturally inspired mechanism rather than more invasive interventions. If the upcoming trial continues to demonstrate encouraging safety and efficacy signals, it could represent a meaningful advance for patients living with neurotrophic keratitis, a condition that currently has few targeted treatment options.

    The progress of Lacripep also reflects the broader promise of peptide-based therapeutics in ophthalmology, where naturally derived molecules are increasingly being explored for their ability to support tissue repair with a favorable safety profile. As TearSolutions moves forward with this next phase of testing, the eye care community will be watching closely for results that could expand treatment possibilities for this challenging condition.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis – Ophthalmology Times Europe

  • Croatian Scientists’ 1990s Peptide Discovery Gains Mainstream Attention in the US

    Croatian Scientists’ 1990s Peptide Discovery Gains Mainstream Attention in the US

    A peptide compound first identified by researchers in Croatia during the 1990s is now experiencing a surge of interest in the United States, bringing renewed attention to the scientists whose early work laid the groundwork for today’s growing peptide research landscape. The story is a reminder that scientific breakthroughs often take unexpected paths before reaching wider recognition.

    The original research, conducted decades ago, explored the properties of a peptide that has since become a subject of interest among researchers and wellness communities alike. As peptide science has expanded rapidly in recent years, driven by advances in synthesis, delivery methods, and a broader understanding of how peptides interact with biological systems, older discoveries like this one are being revisited with fresh eyes and modern tools.

    This kind of cross-generational, cross-border scientific journey highlights something important about the peptide field: foundational research doesn’t lose its value with time. Instead, it often becomes the seed for new investigations, product development, and clinical curiosity years or even decades later. The Croatian team’s early work is now part of a larger conversation happening among scientists, biotech companies, and consumers in the US who are increasingly curious about peptide-based approaches to health and performance.

    For the original researchers, seeing their work move into the spotlight after so many years is a meaningful validation of their early scientific instincts. It also underscores the collaborative, global nature of peptide science, where discoveries made in one country can ripple outward and influence research and innovation elsewhere. As more attention flows toward this compound, it may encourage renewed academic interest, further studies, and a deeper understanding of its properties and potential applications.

    Stories like this help illustrate the long arc of scientific progress, showing how patience, curiosity, and rigorous early research can eventually pay dividends far beyond their original context. As the peptide field continues to grow, we may see more instances of overlooked or under-recognized discoveries finding new audiences and applications.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Croatian researchers thrust into limelight as their 1990sā€™ peptide discovery goes mainstream in the US – Chemistry World

  • Kither Biotech Completes Phase I Trial for Novel Peptide Therapy KIT2014

    Kither Biotech Completes Phase I Trial for Novel Peptide Therapy KIT2014

    Kither Biotech, a biotechnology company focused on developing innovative peptide-based therapeutics, has announced the successful completion of a Phase I clinical trial for its lead candidate, KIT2014. This milestone represents a meaningful step in the ongoing effort to bring new peptide-based treatment options closer to patients who may benefit from them.

    Phase I trials are a critical early stage in the drug development process, designed primarily to evaluate how a new compound behaves in the body and to establish a foundational safety profile. Reaching the completion of this stage is an encouraging sign that the KIT2014 program is progressing along the standard pathway toward further clinical evaluation.

    While detailed results from the trial have not yet been fully disclosed, the completion itself reflects positive momentum for Kither Biotech and its pipeline of peptide-based candidates. Companies like Kither are part of a growing wave of biotech innovators exploring how peptides can be leveraged to address unmet medical needs across a range of therapeutic areas.

    As the peptide therapeutics space continues to expand, milestones like this help build the broader body of clinical knowledge that supports future innovation. Should KIT2014 continue to advance through subsequent trial phases, it could contribute to the growing toolkit of peptide-based interventions available to clinicians and researchers.

    True North Labs will continue to monitor developments in the KIT2014 program and share updates as more information becomes available. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Kither Biotech concludes Phase I study of KIT2014 – Clinical Trials Arena

  • FDA Panel Set to Reconsider Peptide Restrictions, Signaling Potential for Expanded Access

    FDA Panel Set to Reconsider Peptide Restrictions, Signaling Potential for Expanded Access

    The peptide community may soon see a shift in the regulatory landscape, as an FDA panel is reportedly preparing to revisit restrictions placed on certain peptides during the previous administration. According to reporting from Bloomberg Law, the panel will weigh whether current rules should be loosened, offering a potential opening for expanded access to these popular research and wellness compounds.

    For years, peptides such as BPC-157 and others have generated significant interest among researchers, athletes, and wellness enthusiasts for their potential applications. When restrictions were introduced, many in the field expressed concern that promising avenues for research and development could be slowed. This upcoming review signals that regulators may be willing to reconsider the balance between oversight and accessibility.

    A willingness to revisit prior decisions is itself an encouraging sign. It suggests that the FDA is open to incorporating updated evidence, industry feedback, and outcomes data into its rulemaking process, rather than treating past restrictions as permanent. For researchers and manufacturers who have advocated for clearer, more workable frameworks, this development represents a meaningful opportunity to make their case.

    Should the panel move toward loosening restrictions, the effects could ripple across the peptide industry. Easier regulatory pathways often translate into more research funding, greater investment in quality manufacturing, and increased innovation, as companies and academic institutions gain more confidence to pursue development without the uncertainty of shifting compliance burdens. This, in turn, could benefit patients and consumers by expanding access to well-studied, properly manufactured products.

    It’s worth noting that any regulatory change typically unfolds gradually, with public comment periods, expert testimony, and careful deliberation before new rules take effect. Still, the fact that this topic is back on the table is a positive signal for stakeholders who have been calling for a more balanced, evidence-based approach to peptide regulation. True North Labs will continue to monitor developments as the FDA panel proceeds with its review.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules – Bloomberg Law News

  • New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity

    New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity

    Researchers have launched a clinical trial to evaluate NT 201, a botulinum toxin-based therapy, as a potential treatment for lower limb spasticity resulting from stroke or traumatic brain injury. Spasticity, a common and often painful condition marked by muscle stiffness and involuntary contractions, can significantly limit mobility and quality of life for survivors of these conditions. This study represents an important step toward expanding treatment options for patients navigating long-term recovery.

    The trial is structured as a randomized, placebo-controlled study, considered the gold standard in clinical research. Participants will be randomly assigned to receive either a single 400-unit dose of NT 201 or a placebo, with neither participants nor research staff aware of who receives which treatment. This rigorous design helps ensure that any observed benefits can be attributed to the treatment itself rather than other factors, giving future results strong scientific credibility.

    Following the initial phase, the study includes an open-label extension period in which all participants will receive active treatment for four to five additional cycles, with doses ranging from 400 to 800 units depending on whether spasticity affects only the lower limb or both the upper and lower limbs. This extended phase will allow researchers to gather valuable data on the long-term safety and tolerability of repeated treatments, information that could help shape future dosing guidelines and treatment protocols.

    Botulinum toxin therapies have already shown promise in treating various forms of muscle spasticity, and this trial builds on that foundation by focusing specifically on the needs of stroke and traumatic brain injury survivors. If successful, this research could offer clinicians additional evidence-based options to help patients regain mobility and independence during rehabilitation.

    Trials like this one are essential to advancing the field of neurorehabilitation, offering hope that more effective, well-studied treatments may become available for people managing the aftermath of stroke or brain injury. As the study progresses, its findings will contribute to the broader understanding of how peptide-based and toxin-based therapies can support recovery and improve daily functioning.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

  • New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers

    New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers

    Researchers are launching a promising new Phase III clinical trial, known as the IMPACT Trial, to evaluate an innovative treatment approach for patients facing unresectable appendix or colorectal cancer that has spread to the lining of the abdominal cavity, a condition known as peritoneal metastases. This is a particularly challenging diagnosis, and the trial represents a hopeful step toward expanding treatment options for these patients.

    The study will examine Pressurized Intraperitoneal Aerosolized Chemotherapy, or PIPAC, using the drug mitomycin. Unlike traditional chemotherapy infusions delivered through a vein, PIPAC works by delivering chemotherapy as a fine, pressurized mist directly into the abdominal cavity during a minimally invasive laparoscopic procedure. This technique allows the medication to be absorbed more evenly by cancerous tissue while avoiding the need for more invasive open surgery, and it can potentially be repeated multiple times as needed.

    In the trial, patients will receive PIPAC with mitomycin in combination with the standard FOLFIRI chemotherapy regimen, with or without the antiangiogenic drug bevacizumab, and researchers will compare outcomes to those receiving standard FOLFIRI plus bevacizumab alone. The goal is to determine whether this combined, localized-and-systemic approach can offer better results than standard intravenous chemotherapy by itself.

    What makes this approach especially encouraging is its minimally invasive nature and the potential for more targeted, effective delivery of cancer-fighting medication directly where it’s needed most. For patients whose tumors cannot be surgically removed, having additional treatment options that are both innovative and less physically taxing represents meaningful progress in the field of oncology. Trials like IMPACT reflect the ongoing efforts of the medical research community to refine and improve care for people facing difficult-to-treat cancers.

    While it will take time before results are available, the initiation of this Phase III trial marks an important and hopeful development for patients and families affected by appendix and colorectal cancers with peritoneal spread. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

  • New Clinical Trial Explores Advanced Combination Therapy for Aggressive Lymphoma

    A new clinical trial, known as waveLINE-011, is underway to evaluate innovative treatment combinations for germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL), an aggressive form of blood cancer. The study represents an important step forward in the ongoing effort to identify more effective therapies for patients facing this challenging diagnosis.

    Researchers are comparing two treatment approaches: one combining zilovertamab vedotin (MK-2140) with the established R-CHP regimen (rituximab, cyclophosphamide, doxorubicin, and prednisone), and another using polatuzumab vedotin alongside the same R-CHP backbone. Both zilovertamab vedotin and polatuzumab vedotin belong to a class of medications called antibody-drug conjugates, which are designed to deliver cancer-fighting agents directly to malignant cells while aiming to minimize harm to healthy tissue.

    The primary goal of this study is to determine which combination leads to a greater proportion of patients achieving a complete response, meaning the cancer becomes undetectable following treatment. By directly comparing these two approaches within the GCB DLBCL patient population, researchers hope to gather valuable data that could help refine treatment standards for this specific subtype of lymphoma.

    This type of head-to-head clinical comparison is particularly valuable because it allows the medical community to build a clearer picture of which therapies may offer the most benefit for specific patient populations. GCB DLBCL affects younger, still-maturing B-cells, and studies like this one help researchers understand how best to target this particular disease subtype with increasingly sophisticated treatment options.

    The initiation of this trial reflects the continued momentum in oncology research toward refining and improving combination therapies for blood cancers. As enrollment and data collection progress, the findings from waveLINE-011 could contribute meaningfully to future treatment guidelines for people with this diagnosis. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)